Anavex Life Sciences Corp (AVXL)

[Gator328]

I’m not sure I understand why the second option is riskier, other than maybe in terms of delaying approval.

If the FDA doesn’t accept S1R as a biomarker, I’d guess it would be more likely to require an additional trial than to reject A273 outright with no more shots on goal.

The risk is more with the delay in getting ti market than being forced to pivot to another pipeline drug because A273 was deemed ineffective.